Consensus Henry Schein, Inc.

Equities

HSIC

US8064071025

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq Other stock markets 04:00:00 2026-01-20 pm EST			5-day change	1st Jan Change
77.73 ^USD	-2.81%		+2.52%	+2.84%

12:13pm	Mizuho Adjusts Price Target on Henry Schein to $81 From $74, Maintains Neutral Rating	MT
Jan. 18	Tetratherix Secures Distribution Deal With Healthcare Product Distributor; Shares Up 3%	MT

Evolution of the Average Target: Henry Schein, Inc.

Evolution of the Target Price: Henry Schein, Inc.

Changes in Analyst Recommendations: Henry Schein, Inc.

82d8194a228022772a56ad4.1sSFIB6uKpyeAbpo5-fnnO1_pGbhUjkO9Dk4sbT6DMo.hqzQZkbtUOrEUP9fgom4zrkW-z6FA39gn0tX5N2_OYGGqP9hROVnrPt1yQ~f976c360167dc72352bd9410883bbcfd

Analysts' recommendations: Henry Schein, Inc.

12:13pm	Mizuho Adjusts Price Target on Henry Schein to $81 From $74, Maintains Neutral Rating	MT
Dec. 09	Barclays Initiates Henry Schein With Overweight Rating, $86 Price Target	MT
Nov. 05	JPMorgan Adjusts Price Target on Henry Schein to $78 From $80, Maintains Overweight Rating	MT
Nov. 05	Morgan Stanley Adjusts Price Target on Henry Schein to $58 From $55, Maintains Underweight Rating	MT
Nov. 05	Baird Adjusts Price Target on Henry Schein to $78 From $72, Maintains Neutral Rating	MT
Nov. 05	Stifel Adjusts Price Target on Henry Schein to $72 From $70, Maintains Neutral Rating	MT
Nov. 05	Evercore ISI Adjusts Price Target on Henry Schein to $90 From $83, Maintains Outperform Rating	MT
Nov. 04	MORNING BID AMERICAS-Nerves rising about frothy valuations	RE
25-10-27	Barrington Research Adjusts Henry Schein Price Target to $56 From $78	MT
25-10-14	Leerink Partners Adjusts Price Target on Henry Schein to $71 From $72, Maintains Market Perform Rating	MT
25-10-02	Barrington Research Maintains Price Target on Henry Schein at $78, Rating is Outperform	MT
25-10-02	Barrington Research Adjusts PT on Henry Schein to $56 From $78, Maintains Outperform Rating	MT
25-08-26	Henry Schein Shares Rise After Evercore ISI Upgrade	MT
25-08-26	Evercore ISI Upgrades Henry Schein to Outperform From In Line, Adjusts Price Target to $83 From $70	MT
25-08-06	Barrington Adjusts Price Target on Henry Schein to $78 From $90, Maintains Outperform Rating	MT
25-08-06	UBS Adjusts Price Target on Henry Schein to $70 From $75, Maintains Neutral Rating	MT
25-08-06	Stifel Adjusts Price Target on Henry Schein to $70 From $75, Maintains Neutral Rating	MT
25-08-06	Evercore ISI Adjusts Price Target on Henry Schein to $70 From $78, Maintains In Line Rating	MT
25-08-06	Leerink Partners Adjusts Price Target on Henry Schein to $72 From $75, Maintains Market Perform Rating	MT
25-08-06	Mizuho Adjusts Price Target on Henry Schein to $74 From $76, Maintains Neutral Rating	MT
25-08-06	Jefferies Adjusts Price Target on Henry Schein to $72 From $77, Maintains Hold Rating	MT
25-07-25	Henry Schein Shares Decline After Stifel Downgrade	MT
25-07-25	Stifel Downgrades Henry Schein to Neutral From Buy, Adjusts Price Target to $75 From $80	MT
25-07-14	Baird Downgrades Henry Schein to Neutral From Outperform, Adjusts Price Target to $72 From $82	MT
25-07-09	Evercore ISI Adjusts Price Target on Henry Schein to $78 From $72	MT

More recommendations

Sector Comparison:

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
HENRY SCHEIN, INC.				-2.92%
SHIP HEALTHCARE HOLDINGS, INC.				+6.77%
AS ONE CORPORATION				+39.77%
EXCELSIOR MEDICAL CO., LTD.	-	-	-	+11.19%
Average				+13.70%
Weighted average by Cap.				+2.52%

See all sector consensus

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

79.98USD

Average target price

77.64USD

Spread / Average Target

-2.92%

High Price Target

90.00USD

Spread / Highest target

+12.53%

Low Price Target

58.00USD

Spread / Lowest Target

-27.48%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

Barclays
JPMorgan Chase
Evercore ISI
Stifel Nicolaus
Baird
Morgan Stanley
Barrington Research
Leerink Partners
UBS
Jefferies & Co.
Mizuho Securities
Wells Fargo Securities
BofA Securities
Goldman Sachs
Piper Sandler
Credit Suisse